Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 3 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 34Lung Neoplasms 11Neoplasms 4Adenocarcinoma of Lung 4Brain Neoplasms 3Adenocarcinoma, Bronchiolo-Alveolar 3Neoplasm Metastasis 2NSCLC 2Urinary Bladder Neoplasms 1Thoracic Neoplasms 1Stage IV EGFR Mutated Non-Small Cell Lung Cancer 1Squamous Cell Carcinoma of Head and Neck 1Respiratory Tract Diseases 1Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer 1Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer 1Head and Neck Neoplasms 1EGFR Tyrosine Kinase Inhibitors Plus VEGFR Inhibitors 1Carcinoma 1Breast Neoplasms 1Advanced Non-small Cell Lung Cancer 1Adenocarcinoma 1

Interventions

Leucovorin 22Fluorouracil 22Gemcitabine 21Capecitabine 21Paclitaxel 20Docetaxel 20Irinotecan 15Carboplatin 15Radiosurgery 14Oxaliplatin 13Cisplatin 13Bevacizumab 13Zoledronic Acid 12pembrolizumab 11Radiotherapy 11Fulvestrant 11palbociclib 9Pemetrexed 9Drug Therapy 9130-nm albumin-bound paclitaxel 9Surgical Procedures, Operative 7Letrozole 7Ibandronic Acid 7abemaciclib 6Trastuzumab 6Prednisone 6Vinorelbine 5Folfox protocol 5Floxuridine 5Doxorubicin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Neoplasm Metastasis × Gefitinib × Clear all
NCT01774721 2023-11-14

ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.

Pfizer

Phase 3 Completed
452 enrolled 35 charts 1 FDA
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT00034879 2013-01-04

Iressa Expanded Access Program (EAP)

AstraZeneca

Phase 3 Completed
Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡